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INTRODUCTION
Synchronous malignant tumours of the female genital tract are a rare but known phenomenon, with an incidence of only 0.7%. 1 Approximately 50% of synchronous gynaecolog ical malignancies are synchronous tumours of the uterus and ovary (STOUs). 2 The most common variant of STOUs is the combination of endometrioid carcinomas of the ovary and endometrium, while the occurrence of uterine stromal sarcoma and adenocarcinoma of the ovary has not been yet described in the literature. The diagnosis and treatment of STOUs is no different from the diagnosis and treatment of solitary cancers of the female genital tract. The treatment of choice is surgery, and additional therapeutic procedures, such as chemotherapy and radiotherapy, are used depending on the stage of the disease and histological type of the tumour.
CASE REPORT
A 53-year-old female patient who was multiparous, in menopause and had a medium body composition reported to the ambulatory gynaecological examination service after irregular uterine haemorrhaging. The haemorrhaging had occurred for the first time since the patient had entered menopause, and she reported no other symptoms. Her medical history indicated that menarche had started at 14 years, and her last regular menstrual cycle was at 51 years of age. The patient did not use oral contraceptive pills or hormone replacement therapy. A bimanual gynaecologic examination was conducted and showed an enlarged uterus. The cervical examination identified a whitish lesion protruding from the endocervical canal. A cervical biopsy was performed, and a spotted lesion of approximately 6 mm was excised. Haematoxylin-eosin (HE) staining indicated the existence of a tumour with a high-grade malignancy. The differential diagnosis included poorly differentiated adenocarcinoma, stromal sarcoma and mixed Mullerian tumour . It was suggested that a definitive histological diagnosis with the simultaneous staging of the disease could be made after analysing the postoperative materials. Before the operation, the patient underwent ultrasonography (ECHO) and computed tomography. Transabdominal ECHO showed an enlarged uterus, 210x130 mm in diameter, with a wall thickness of up to 70 mm and a right adnexal solid mass, 125x58 mm in diameter. In addition to visualizing the enlarged uterus and right adnexal mass, computed tomography (CT) of the abdomen and pelvis indicated the existence of focal intra- peritoneal metastases. CT of the thorax and a bone scan did not register pathomorphological changes. The gynaecological council decision was to carry out radical surgical treatment due to the possibility of metastases in the right adnexa. The patient underwent exploratory laparotomy, total hysterectomy, lymphanodectomy , total omentectomy, peritoneal biopsy, and peritoneal lavage.
A histopathologic analysis was performed. The uterus, left adnexa and right fallopian tube were initially submitted together, while the right ovarian tumour, samples of the omentum and peritoneum, 30 lymph nodes and 12 ml of ascites fluid were submitted separately. The uterus weight was 700 g, and it was 184x136x84 mm in diameter, while the cervix was 38 mm long with a protruding tumour mass (Figure 1a) . The tissue cross section demonstrated that the walls of the uterus and cervix were infiltrated by a grey tumour mass, with yellowish areas of necrosis and red areas of haemorrhage. Tumours with similar macroscopic characteristics filled the lumen and infiltrated the walls of both fallopian tubes. The largest diameter of the left ovary was 24 mm, with no visible macroscopic changes (Figure 1b) . The right ovarian tumour was enlarged to 72x44 mm in diameter , with a solid and partly cystic structure at the cross section (Figure 2a, b) . The adipose tissue in the omental and peritoneal samples was of regular morphology, and the lymph node structure was homogeneous, with diameters ranging from 7 to 15 mm.
Microscopically, the existence of two morphologically distinct tumours was confirmed. HE staining showed characteristics similar to the tissues of the uterus, cervix and fallopian tubes. The tumour was present in all layers of the uterus wall, with infiltrations into the cervix and fallopian tubes. The tumour contained extensive areas of necrosis and areas of angioinvasion and was composed of small and moderately sized cells, with scant cytoplasms and blurred cell boundaries. The nuclei were vesicular, with prominent nucleoli and numerous mitotic figures (over 30/10 HPF) (Figure 3a) . Immunohistochemically, the tumour cells were diffusely positive for only vimentin and remained negative for CD10, S-100, actin, desmin, LCA, EMA, CKAE1/AE3, ER, PR and CA125 (Figure  3b-d) . Based on the microscopic analysis and the tumour cell immunophenotype, the diagnosis of a high-grade endometrial stromal sarcoma, FIGO stage IIIa, was made. 3 A microscopic analysis of the HE-stained samples that matched the cyst found in the right ovary revealed a tumour composed of pseudo-glandular, cribriform and solid areas of atypical, cylindrical and cuboidal cells with eosinophilic cytoplasms (Figure 4a ). The nucleoli were hyperchromatic or vesicular, with a moderate number of mitotic figures. The stoma was relatively sparse and contained an inflammatory mononuclear cell infiltrate (Figure 4b) . Immunohistochemically, the tumour cells were positive for CK7, CA125, ER and PR and remained negative for vimentin and CEA. The proliferation index was intermediate, with approximately 25% of the nuclei expressing Ki-67 (Figure 4c-f ) . Based on the immunophenotype, the diagnosis of a moderately differentiated endometrioid carcinoma of the ovary with no tumour extension (FIGO Ia stage) was made. The left ovary, lymph nodes, and tissue samples of the omentum and peritoneum were all free of tumour deposits. Finally, a cytological analysis of the peritoneal lavage fluid showed no presence of malignant cells. The postoperative course passed without complication, and the patient was released from the hospital on the 10th postoperative day. The oncology council decided to continue the course of treatment with chemotherapy and radiotherapy. However, despite the therapeutic measures implemented, the disease progressed, and secondary deposits were identified in the liver; the patient died 12 months after the diagnosis.
DISCUSSION
Synchronous malignant tumours of the female genital tract are rare, with an incidence ranging from 0.7% to 6%. 1, 4, 5 They are typically localised in the uterus and ovaries and are rarely found in the cervix and ovaries or cervix and uterus. 6, 7 The phenomenon of more than two simultaneous tumours is extremely rare, although Atasever et al previously described up to 5 simultaneous ovarian cancers in one patient. 8 Studies have shown that approximately 50% of synchronous gynaecological malignancies are tumours of the uterus and ovaries. 2 Their incidence and prevalence is still a subject of debate because of the large differences in the observed results, which are primarily due to different research approaches. 9 For instance, population studies including women with ovarian cancer have reported an incidence of less than 3%, while analyses of first-stage endometrial carcinoma have reported an incidence of STOUs of 0.31% . [10] [11] [12] Zaino et al have claimed that the incidence of STOUs in women with ovarian cancer is 10% and no more than 5% in women with endometrial cancer, while Irving has reported an incidence of 15-20%. 13, 14 This inconsistency is associated with the different characteristics of the analysed populations, sample size, more organised prevention methods and more precise diagnostics. This is particularly important in the case of cancers with identical endometrioid histological types, with many previously well-defined pathomorphological criteria for the detection of STOUs. 15, 16 The histopathological diagnosis of different histological types of STOUs is not a problem due to the clearly defined microscopic images and different tumour immunophenotypes.
The most common histological type of STOUs is endometrioid carcinoma in both locations. 17 Serous and clearcell carcinomas are less frequent, and few cases, if any, are HE staining technique, x400) . Immunohistochemically, the tumour cells were positive for c) ER (x400) and d) CK7 (x400) and remained negative for e) vimentin (x200). f) Th e proliferation index was intermediate, and approximately 25% of the nuclei expressed Ki-67 (x400).
related to the combination of granulosa cell tumour of the ovary and endometrial carcinoma. 18 In a series of 30 cases of STOUs, Rodolakis et al described only one case of uterine endometrioid carcinoma and carcinosarcoma of the ovary. 19 The relatively small number of individual cases of non-endometrioid types of STOUs is the most likely reason for the lack of their precise analysis. 6 Ours is the first report of STOUs with endometrial stromal sarcoma (SSE) and endometrioid carcinoma of the ovary.
SSE is the second most common mesenchymal tumour of the uterus, with a prevalence of 10% among all malignancies with a mesenchymal component. 20 According to the WHO classification, uterine sarcomas are classified into two categories: low-grade SSE and undifferentiated SSE. 21 Low-grade malignant SSE typically consists of tumour cells similar to stromal cells in the proliferative phase of the menstrual cycle, which infiltrate the myometrium, parametrium and surrounding lymph vessels. In contrast, undifferentiated SSE is characterised by the absence of stromal differentiation and is referred to as poorly differentiated or high-grade undifferentiated. Endometrioid carcinomas are present in approximately 10-30% of malignant ovarian tumours, bilateral in 28% of cases and most frequent in the fifth and sixth decades of life. They derive from epithelial metaplasia or the focus of ovarian endometriosis and by definition are made of cells resembling the endometrial epitheluim. 21 A potential reason for the identification of STOUs comprising SSE and endometrioid carcinoma may be the existence of adenomyosis and ovarian endometriosis. 22.23 Various genetic, embryonic and hormonal factors are possible reasons for the phenomenon of STOUs. 24 STOUs are thought to be associated with hyperoestrogenism during chronic anovulation, polycystic ovary syndrome, obesity, oestrogen-producing ovarian tumours and hormone therapy. 25 The multiple genetic alterations observed suggest that the tumours develop independently, 14 and Lynch syndrome is present in 7-9% of patients with STOUs. 26, 27 Most likely, STOUs are caused by different and still unknown aetiological factors. 28 The average age of patients with STOUs is 49-52 years. 6, 13 In contrast to STOUs, ovarian and endometrial cancers occur in older, multiparous, postmenopausal, obese women who often suffer from diabetes or hypertension. 2 The patient we presented was 52 years old and multiparous with no other features characteristic of patients with STOUs.
The GOG study showed that patients with STOUs have a much better prognosis compared with patients with metastatic ovarian and endometrial cancers. The ten-year survival rate is 80%, and it is mainly related to the most common endometrioid/endometrioid type of STOUs. 6, 13 The better prognosis of STOUs is most likely due to the early detection of ovarian cancer because the illness typically presents as abnormal bleeding from the uterus. 19 This does not apply to our patient, in whom the disease was discovered in an advanced stage, which is why her overall survival was only thirteen months. The best course of treatment is surgery with adjuvant chemotherapy and radiotherapy. Despite all the available treatment measures, most patients do not live for more than two years after the diagnosis due to the occurrence of metastasis or relapse within the first six months of this pernicious illness.
29
CONCLUSION
The prognosis of synchronous tumours of the ovary and the uterus is primarily dependent on the stage and histological type of each tumour. Because of the rather small number of reported cases, a large part of this phenomenon remains unknown. Our report is the first description of the synchronous occurrence of endometrial ovarian carcinoma and uterine stromal sarcoma.
